Blueprint Medicines Corp’s filing revealed that its CHIEF OPERATING OFFICER Rossi Christina unloaded Company’s shares for reported $0.22 million on Mar 24 ’25. In the deal valued at $95.02 per share,2,274 shares were sold. As a result of this transaction, Rossi Christina now holds 69,266 shares worth roughly $6.15 million.
Then, Christina Rossi bought 9,096 shares, generating $811,363 in total proceeds.
Before that, Albers Jeffrey W. sold 5,766 shares. Blueprint Medicines Corp shares valued at $512,021 were divested by the Director at a price of $88.80 per share. As a result of the transaction, Albers Jeffrey W. now holds 146,630 shares, worth roughly $13.01 million.
A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in mid March with a ‘”an Outperform”‘ rating. Jefferies began covering BPMC with “Buy” recommendation on March 17, 2025. Scotiabank started covering the stock on March 07, 2025. It rated BPMC as “a Sector outperform”.
Price Performance Review of BPMC
On Friday, Blueprint Medicines Corp [NASDAQ:BPMC] saw its stock fall -1.13% to $88.72. Blueprint Medicines Corp shares have risen nearly 1.72% since the year began. Nevertheless, the stocks have fallen -1.06% over the past one year. While a 52-week high of $121.90 was reached on 01/27/25, a 52-week low of $80.68 was recorded on 03/10/25. SMA at 50 days reached $98.32, while 200 days put it at $96.80.
Levels Of Support And Resistance For BPMC Stock
The 24-hour chart illustrates a support level at 87.57, which if violated will result in even more drops to 86.41. On the upside, there is a resistance level at 89.84. A further resistance level may holdings at 90.95. The Relative Strength Index (RSI) on the 14-day chart is 43.40, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.61, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 67.72%. Stochastics %K at 43.63% indicates the stock is a holding.
How much short interest is there in Blueprint Medicines Corp?
A steep rise in short interest was recorded in Blueprint Medicines Corp stocks on 2025-03-14, growing by 0.12 million shares to a total of 5.02 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 4.9 million shares. There was a rise of 2.39%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 14, 2024 when JP Morgan began covering the stock and recommended ‘”an Overweight”‘ rating along with a $126 price target.
